Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Mechanisms of the HRSL3 tumor suppressor function in ovarian carcinoma cells
Irina Nazarenko*,
Reinhold Schäfer, and
Christine Sers
Molecular Tumor Pathology, Institute of Pathology, University Medicine Charité Berlin, Schumannstrasse 20/21, 10117 Berlin, Germany
Author for correspondence (e-mail: christine.sers{at}charite.de)
Accepted for publication 29 January 2007.
Abstract:
HRSL3 (also known as H-REV107-1) belongs to a class II tumorsuppressor gene family and is downregulated in several humantumors including ovarian carcinomas. To unravel the mechanismof HRSL3 tumor suppressor action, we performed a yeast two-hybridscreen and identified the -isoform of the regulatory subunitA of protein phosphatase 2A (PR65) as a new interaction partnerof HRSL3. Interaction between HRSL3 and PR65 was confirmed invitro and by co-immunoprecipitation in mammalian cells. We demonstratethat HRSL3 binds to the endogenous PR65, thereby partially sequesteringthe catalytic subunit PR36 from the PR65 protein complex, andinhibiting PP2A catalytic activity. Furthermore, binding ofHRSL3 to PR65 induces apoptosis in ovarian carcinoma cells ina caspase-dependent manner. Using several mutant HRSL3 constructs,we identified the N-terminal proline-rich region within theHRSL3 protein as the domain that is relevant for both bindingof PR65 and induction of programmed cell death. This suggeststhat the negative impact of HRSL3 onto PP2A activity is importantfor the HRSL3 pro-apoptotic function and indicates a role ofPP2A in survival of human ovarian carcinomas. The analysis ofdistinct PP2A target molecules revealed PKC as being involvedin HRSL3 action. These data implicate HRSL3 as a signaling regulatorymolecule, which is functionally involved in the oncogenic networkmediating growth and survival of ovarian cancer cells.
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORS' CHOICE
John F. Foley (10 April 2007) Sci. STKE2007 (381), tw126.
[DOI: 10.1126/stke.3812007tw126] |Abstract »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Evolution of Retinoid and Steroid Signaling: Vertebrate Diversification from an Amphioxus Perspective.
R. Albalat, F. Brunet, V. Laudet, and M. Schubert (2011)
Genome Biol Evol
3, 985-1005
|Abstract »|Full Text »|PDF »
The DNA binding factor Hmg20b is a repressor of erythroid differentiation.
F. Esteghamat, T. B. van Dijk, H. Braun, S. Dekker, R. van der Linden, J. Hou, P. Fanis, J. Demmers, W. van IJcken, Z. Ozgur, et al. (2011)
Haematologica
96, 1252-1260
|Abstract »|Full Text »|PDF »
Atypical Protein Kinase C {zeta} Exhibits a Proapoptotic Function in Ovarian Cancer.
I. Nazarenko, M. Jenny, J. Keil, C. Gieseler, K. Weisshaupt, J. Sehouli, S. Legewie, L. Herbst, W. Weichert, S. Darb-Esfahani, et al. (2010)
Mol. Cancer Res.
8, 919-934
|Abstract »|Full Text »|PDF »
The tumor suppressor gene H-Rev107 functions as a novel Ca2+-independent cytosolic phospholipase A1/2 of the thiol hydrolase type.
T. Uyama, J. Morishita, X.-H. Jin, Y. Okamoto, K. Tsuboi, and N. Ueda (2009)
J. Lipid Res.
50, 685-693
|Abstract »|Full Text »|PDF »
Identification and Functional Characterization of Adipose-specific Phospholipase A2 (AdPLA).
R. E. Duncan, E. Sarkadi-Nagy, K. Jaworski, M. Ahmadian, and H. S. Sul (2008)
J. Biol. Chem.
283, 25428-25436
|Abstract »|Full Text »|PDF »